These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 27648660)

  • 1. Frequent nocturia episodes, a suboptimal response to treatment, and small bladder capacity predict the need for persistent antimuscarinic therapy or re-treatment after discontinuation of antimuscarinics in female overactive bladder.
    Hsiao SM; Chang TC; Chen CH; Wu WY; Lin HH
    Menopause; 2017 Jan; 24(1):100-104. PubMed ID: 27648660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The probability of re-treatment after discontinuation of a 3-month versus a 6-month course of solifenacin for female overactive bladder: A prospective randomized controlled study.
    Hsiao SM; Chang TC; Lin HH
    Maturitas; 2019 Aug; 126():11-17. PubMed ID: 31239111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary nerve growth factor and a variable solifenacin dosage in patients with an overactive bladder.
    Ciftci S; Ozkurkcugil C; Yilmaz H; Ustuner M; Yavuz U; Yuksekkaya M; Cekmen MB
    Int Urogynecol J; 2016 Feb; 27(2):275-80. PubMed ID: 26310546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with a better therapeutic effect of solifenacin in patients with overactive bladder syndrome.
    Hsiao SM; Lin HH; Kuo HC
    Neurourol Urodyn; 2014 Mar; 33(3):331-4. PubMed ID: 23494586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms.
    Brubaker L; FitzGerald MP
    Int Urogynecol J Pelvic Floor Dysfunct; 2007 Jul; 18(7):737-41. PubMed ID: 17131169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients.
    Wang CC; Kuo HC
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):279-284. PubMed ID: 29843924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy.
    Liu HT; Lin H; Kuo HC
    Neurourol Urodyn; 2011 Nov; 30(8):1525-9. PubMed ID: 21826717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Gabapentin in Comparison to Solifenacin Succinate in Adult Overactive Bladder Treatment.
    Chua ME; See MC; Esmeňa EB; Balingit JC; Morales ML
    Low Urin Tract Symptoms; 2018 May; 10(2):135-142. PubMed ID: 28150436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autonomic dysfunction and arterial stiffness in female overactive bladder patients and antimuscarinics related effects.
    Hsiao SM; Su TC; Chen CH; Chang TC; Lin HH
    Maturitas; 2014 Sep; 79(1):65-9. PubMed ID: 25022469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychometric assessment of female overactive bladder syndrome and antimuscarinics-related effects.
    Hsiao SM; Liao SC; Chen CH; Chang TC; Lin HH
    Maturitas; 2014 Dec; 79(4):428-34. PubMed ID: 25238744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of Daytime or Nighttime Dosing with Solifenacin for Overactive Bladder with Nocturia: Impact on Nocturia and Sleep Quality.
    Kwon T; Oh TH; Choi S; Cho WY; Min K; Lee JZ; Moon KH
    J Korean Med Sci; 2017 Sep; 32(9):1491-1495. PubMed ID: 28776345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for the failure of antimuscarinic treatment with solifenacin in women with overactive bladder.
    Serati M; Braga A; Siesto G; Sorice P; Cattoni E; Uccella S; Cromi A; Salvatore S; Ghezzi F
    Urology; 2013 Nov; 82(5):1044-8. PubMed ID: 24054438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries.
    Aparasu RR; Sura S; Earla JR; Shiozawa A; Ng DB; Schermer CR
    Adv Ther; 2020 Aug; 37(8):3584-3605. PubMed ID: 32638205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence of solifenacin therapy in patients with overactive bladder in the clinical setting: a prospective, multicenter, observational study.
    Kim TH; You HW; Park JH; Lee JG; Choo MS; Park WH; Lee JZ; Park CH; Na YG; Kwon DD; Lee KS
    Int J Clin Pract; 2016 Apr; 70(4):351-7. PubMed ID: 27028673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
    Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
    Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment.
    Chou EC; Hung MJ; Yen TW; Chuang YC; Meng E; Huang ST; Kuo HC
    J Formos Med Assoc; 2014 Aug; 113(8):506-12. PubMed ID: 25037757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of dose escalation in male patients with overactive bladder showing poor efficacy after low-dose antimuscarinic treatment: A retrospective multicenter study.
    Shim M; Kim JK; Bang WJ; Lee YS; Cho ST; Cho JS; Joo KJ; Hyun JS; Kim BH; Lee JB; Seo YJ; Oh CY
    Investig Clin Urol; 2020 Nov; 61(6):600-606. PubMed ID: 32985146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.